Sign inJoin waitlistJoin the waitlist

Anthony Garcia-Prats

Pediatrics

Credentials: · · · · ·

History

Baylor College of Medicine Affiliated Hospitals
2002–2005
Clinical Epidemiology, Stellenbosch University, Cape Town, South Africa
Baylor College of Medicine
1998–2002
St. Louis University, St. Louis, Missouri

Research

Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine · 2025 · 112 citations
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis
Systematic review or meta-analysis · PLoS Medicine · 2018 · 102 citations
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Systematic review or meta-analysis · The Lancet Respiratory Medicine · 2018 · 82 citations

Jennifer Furin
19 papers
Bryan Vonasek
10 papers · 2 as a fellow
Elizabeth Harausz
6 papers · 1 as a fellow
James Nielsen
6 papers
Kelly Dooley
6 papers
Amita Gupta
5 papers
Andrea Cruz
5 papers
EM
Eric McCollum
5 papers
FA
Farhana Amanullah
5 papers · 2 as a fellow
Tania Thomas
5 papers
CP
Charles Peloquin
4 papers
Jeffrey Starke
4 papers

Grants

Re-Evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $2.9M · University of Wisconsin-Madison
2025–2030
Innovative Secondary Analyses of Individual Patient Data to Address Key Evidence Gaps in Pediatric Rifampicin-Resistant TB Treatment
National Institute of Allergy and Infectious Diseases · R03
Contact PI · $92.5K · University of Wisconsin-Madison
2026–2028
Optimizing and Operationalizing Pediatric Drug-Resistant Tuberculosis Treatment
National Institute of Child Health and Human Development · R01
Contact PI · $1.6M · Stellenbosch University
2015–2021

Clinical trials

Re-evaluating the Duration in Children of TB Treatment
Principal investigator · Not yet recruiting · Phase 2
University of Wisconsin, Madison
2026–2030
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
Study chair · Completed · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2019–2025